London’s research focus is in developing novel tools and gene editing strategies for use in targeting and treating pancreatic ductile adenocarcinoma from both preventative and curative perspectives. London joined the institute after receiving her M.S. in Biotechnology from Temple University in 2019, where she investigated the connection between pancreatitis, Type 2 diabetes, and pancreatic ductile adenocarcinoma. In her downtime, London volunteers as a firefighter/EMT at The Community Fire Company of Perryville Maryland Inc.
At the Gene Editing Institute, London’s focus as part of the Precision Genomics group is to help with identifying and working on new clinically relevant genomic targets for which CRISPR-directed gene editing can be utilized as a potential therapeutic. London’s previous work as a member of the Genome Technologies group was in leading the design and implementation of CRISPR/Cas gene editing strategies for clients in Genome Editing Services. Her focus in that group was on the research and development of new tools for increasing precise repair and knockout efficiencies using CRISPR/Cas systems. Her protocols and research models have been utilized throughout the Institute, including in the pre-clinical development of lung cancer therapies by the Oncology Group.
